metaEvidence - study list

meta|evidence oncology

Living systematic review and meta-analysis

multiple myeloma - 2nd line (L2) 1
myofibroblastic tumors
neurofibroma
neutropenia
new pathology
osteosarcoma
ovarian cancer (OC) 9

All treatments
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab plus pomalidomide and dexamethasone

versus all
vs Immunosuppressant
vs pomalidomide based treatment
vs pomalidomide and dexamethasone

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results

delta: difference in rate or median (if available)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open